<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><submitter>Mermet M</submitter><funding>Medical Research Council</funding><funding>Société Française de Rhumatologie (SFR)</funding><funding>Wellcome Trust</funding><pubmed_abstract>Glucagon-like peptide-1 (GLP-1) has previously been shown to be indispensable for optimal bone strength by acting at the bone material level. However, it was not fully clear whether the effects of GLP-1 were mediated by direct or indirect actions on bone cells. In the present study, we were unable to demonstrate the expression of the GLP-1 receptor (GLP-1r) in bone tissue at the gene expression level using qPCR and in situ hybridization, or at the protein level. Furthermore, the peripheral administration of exendin-4, a specific GLP-1r agonist, in ovariectomized (OVX) BALB/c mice enhanced post-yield displacement (18%) and energy-to-fracture (24%), as well as bone volume/total volume (BV/TV) (11%), trabecular number (Tb.N) (6%), and collagen maturity (18%). These bone effects were still obs</pubmed_abstract><journal>American journal of physiology. Endocrinology and metabolism</journal><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7618104</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>The GLP-1 analogue, exendin-4, improves bone material properties and strength through a central relay in ovariectomized mice.</pubmed_title><pmcid>PMC7618104</pmcid><funding_grant_id>MC_UU_12012/3</funding_grant_id><funding_grant_id>220271</funding_grant_id><funding_grant_id>220271/Z/20/Z</funding_grant_id><funding_grant_id>MRC_MC_UU_12012/3</funding_grant_id><funding_grant_id>2020-2650</funding_grant_id><pubmed_authors>Mabilleau G</pubmed_authors><pubmed_authors>Cruciani-Guglielmacci C</pubmed_authors><pubmed_authors>Biggs E</pubmed_authors><pubmed_authors>Denom J</pubmed_authors><pubmed_authors>Mermet M</pubmed_authors><pubmed_authors>Wery M</pubmed_authors><pubmed_authors>Mieczkowska A</pubmed_authors><pubmed_authors>Reimann F</pubmed_authors><pubmed_authors>Gribble F</pubmed_authors><pubmed_authors>Magnan C</pubmed_authors></additional><is_claimable>false</is_claimable><name>The GLP-1 analogue, exendin-4, improves bone material properties and strength through a central relay in ovariectomized mice.</name><description>Glucagon-like peptide-1 (GLP-1) has previously been shown to be indispensable for optimal bone strength by acting at the bone material level. However, it was not fully clear whether the effects of GLP-1 were mediated by direct or indirect actions on bone cells. In the present study, we were unable to demonstrate the expression of the GLP-1 receptor (GLP-1r) in bone tissue at the gene expression level using qPCR and in situ hybridization, or at the protein level. Furthermore, the peripheral administration of exendin-4, a specific GLP-1r agonist, in ovariectomized (OVX) BALB/c mice enhanced post-yield displacement (18%) and energy-to-fracture (24%), as well as bone volume/total volume (BV/TV) (11%), trabecular number (Tb.N) (6%), and collagen maturity (18%). These bone effects were still obs</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Aug</publication><modification>2026-06-03T07:44:15.068Z</modification><creation>2026-04-26T03:09:46.942Z</creation></dates><accession>S-EPMC7618104</accession><cross_references><pubmed>40789661</pubmed><doi>10.1152/ajpendo.00086.2025</doi></cross_references></HashMap>